Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
21 hedge funds and large institutions have $26.3M invested in Zynerba Pharmaceuticals, Inc in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 12 closing their positions.
75% more capital invested
Capital invested by funds: $15M → $26.3M (+$11.3M)
19% less funds holding
Funds holding: 26 → 21 (-5)
39% less call options, than puts
Call options by funds: $191K | Put options by funds: $315K
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$551K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$328K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$216K |
| 4 |
PA
Perceptive Advisors
New York
|
+$186K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.74M |
| 2 |
NC
Nexthera Capital
New York
|
-$391K |
| 3 |
AGM
Alpine Global Management
New York
|
-$113K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$111K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$87K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
26
Paloma Partners
Greenwich,
Connecticut
| – | -$87K | -12,750 | Closed |
|
27
Bank of New York Mellon
New York
| – | -$69K | -10,129 | Closed |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$27K | -3,943 | Closed |
|
|
PCM
29
Prelude Capital Management
New York
| – | -$14K | -2,000 | Closed |
|
30
New York State Common Retirement Fund
Albany,
New York
| – | -$12K | -1,800 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$7K | -1,018 | Closed |
|
32
Barclays
London,
United Kingdom
| – | -$3K | -371 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$2K | -224 | Closed |
|
ZYNE Hedge Fund Activity: Q3 2016 in Review
21 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2016, worth a combined $26.3M — up 75% from $15M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ZYNE and 7 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 7 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $551K. The largest seller was RA Capital Management, exiting entirely with an estimated $1.74M sold.
- 21 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2016, down from 26 in Q2 2016.
- Funds reported $26.3M of Zynerba Pharmaceuticals, Inc stock for Q3 2016, up 75% quarter-over-quarter.
- 7 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2016 and 12 closed out, a net change of -5 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2016 was Bridgeway Capital Management, an estimated $551K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2016 was RA Capital Management, an estimated $1.74M sold.
Based on aggregated 13F filings for Q3 2016.